Physician
Vozenilek, John
Vozenilek, John was paid $1.94M by Medicaid between Aug 2018 and Mar 2021, across 36 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 63% of everything it billed.
33Billing provider infoVOZENILEK, JOHN
EVANSTON, IL 60201
EVANSTON, IL 60201
33aNPI1760412910assigned 07/04/2006
33bProvider typeEmergency Medicine Physician
28Total paid$1.94M
24GClaims61,855
24DCodes billed36
24AFirst – last monthAug 2018 – Mar 2021
Compared with peers
Next to other Emergency Medicine Physician providers in Illinois
Rank by total paid#2 of 1,980
Median peer was paid$150K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,096 | $99K | |
| 2019 | 21,829 | $675K | |
| 2020 | 27,905 | $862K | |
| 2021 | 9,025 | $304K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 63% | 32,432 | 23,015 | $1.23M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.0% | 2,662 | 2,033 | $156K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.6% | 4,252 | 2,908 | $109K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5.5% | 6,930 | 5,067 | $106K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 5.2% | 2,406 | 1,761 | $101K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.3% | 2,900 | 1,955 | $83K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.9% | 1,858 | 1,524 | $57K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 924 | 790 | $22K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 232 | 218 | $14K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 666 | 639 | $10K |
| 73610 | <1% | 283 | 275 | $7K | |
| 73630 | <1% | 360 | 349 | $7K |
24 more codes
| 81002 | <1% | 2,698 | $7K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 120 | $7K |
| 73130 | <1% | 245 | $4K | |
| 90686 | <1% | 219 | $4K | |
| 81025 | <1% | 889 | $3K | |
| 87807 | <1% | 279 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 153 | $2K |
| 99384 | <1% | 33 | $2K | |
| 69209 | <1% | 248 | $2K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 34 | $1K |
| 99383 | <1% | 22 | $1K | |
| 73110 | <1% | 55 | $1K | |
| 12001 | <1% | 14 | $841.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 441 | $605.43 |
| 73564 | <1% | 13 | $246.62 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23 | $225.63 |
| 73140 | <1% | 15 | $216.99 | |
| 81003 | <1% | 98 | $203.17 | |
| 82962 | <1% | 64 | $119.60 | |
| 86308 | <1% | 15 | $72.60 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 15 | $17.64 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 59 | $6.69 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 79 | $5.98 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 119 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.